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The predictive value of Helicobacter pylori
in-vitro metronidazole resistance
Resistance to antibiotics and the rate of therapeu-
tic failure with Helicobacter pylori infection are
increasing worldwide. In-vitro sensitivity tests
may help the clinician to establish the correct
therapeutic approach, but in-vitro determination
of resistance to metronidazole poses particular
problems for clinical microbiologists that may be
related to bacterial characteristics or to pitfalls in
the technical procedures used to test sensitivity
[1,2]. Henriksen et al. [3] recently highlighted the
influence that the laboratory handling of H. pylori
may have on the results of in-vitro determination
of metronidazole resistance, in that bacterial
storage significantly reduced the rate of metro-
nidazole resistance, and that isolates retaining
in-vitro resistance had significantly higher rates of
treatment failure than isolates that lost resistance
after storage for 3 years. The results of this study
underlined some important questions regarding
microbiological techniques, and indicated the
need to perform experimental studies designed
specifically to help the clinical microbiologist to
improve laboratory results that may guide anti-
microbial therapy.
We have two specific comments on the con-
clusions reached by Henriksen et al. [3]. The first
relates to the possible explanations for the
differences observed in metronidazole suscepti-
bility results after storage. It has been shown by
several groups [4,5] that H. pylori generally
comprises a population heterogeneous for gen-
etic traits and antibiotic resistance. To investigate
the heterogeneity of H. pylori cultured from
gastric biopsies, we recently used a single-colony
approach, based on immediately subculturing
bacterial isolates from each patient to yield 15–20
single colonies. The phenotypic and genotypic
characteristics of each colony were then studied
in parallel. The results showed that a proportion
of the patients carried mixed populations of
antibiotic-sensitive and antibiotic-resistant micro-
organisms [6]. More interestingly, the distribu-
tion of these subpopulations was highly variable
within patients, with metronidazole-resistant
colonies accounting for 40–90% of the entire
bacterial population. It was also demonstrated
that metronidazole resistance was associated
significantly with an intact cag pathogenicity
island, although the composition of this gene
cluster did not affect resistance to clarithromycin
or amoxycillin [6]. Based on these observations, it
can be hypothesised that the differences in
susceptibility testing observed by Henriksen et al.
[3] may result not from true variations in the
susceptibility pattern, but rather from the sub-
culture and expansion of different subpopula-
tions after bacterial retrieval from stored
samples. This could be a consequence of select-
ing colonies that differ from the original used in
antibiotic testing, or might reflect aspects related
to bacterial physiology, such as the limited
regrowth capacity of strains with deletions of
specific genotypic traits under critical culture
conditions, such as those present after cryopre-
servation. Combined phenotypic and genotypic
studies on H. pylori before and after preservation
may help in the further definition of the reasons
for the discrepancies observed when repeating
antibiotic susceptibility tests.
Second, one of the primary aims of the clinical
microbiologist is to reinforce the positive and
negative predictive values of microbiological tests
and to help the clinician to optimise antibiotic
therapy. The data generated by new clinical and
experimental approaches may initially be frustra-
ting, by showing an increasingly complex rela-
tionship between microrganisms and man.
However, such data may subsequently help to
explain discrepancies between laboratory data
and in-vivo results. Our own ongoing studies
demonstrate that each patient may harbour vari-
able percentages of metronidazole-resistant bac-
teria among the entire bacterial population. The
next step should include an analysis of the
possible relationship between the proportion of
resistant bacteria and treatment outcome. These
data will help us to understand whether treat-
ment failure depends on the ‘load’ of resistant
bacteria or on other unknown factors. Molecular
biology studies have suggested interesting func-
tional relationships between different genomic
traits of H. pylori. In particular, it has been shown
that the composition of the cag island greatly
affects bacterial motility, the ability to survive in
different gastric microenvironments, and the
capacity to induce production of proinflamma-
tory cytokines [7–9]. Compared to cagA– strains,
cagA+ strains induce more potent interleukin-8
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production and a greater degree of inflammation,
and favour the penetration of antibiotics into
the gastric mucosa; bacterial genetic traits may
therefore be linked not only to gastric histo-
pathology, but also to the success of antibiotic
treatment.
In conclusion, multiparametric studies are
required to better define the heterogeneous nature
of H. pylori strains colonising humans. A com-
bined approach, including the correlation
between in-vitro antibiotic testing, in-vivo treat-
ment outcome, and bacterial genotypic traits, may
improve our knowledge significantly.
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Antimicrobial resistance of Acinetobacter
spp. in Europe
We congratulate Drs Van Looveren and Goossens
for their excellent review regarding the antimi-
crobial resistance of Acinetobacter spp. in Europe
[1]. We agree with their statement that colistin
should be considered as a therapeutic option in
patients with severe infections caused by multi-
drug-resistant Acinetobacter baumannii strains.
However, we believe that results from recent
studies suggest that colistin is less toxic than
thought previously and reported in the review. In
fact, the reported rates of nephrotoxicity (27%
and 58% in patients with baseline normal and
abnormal renal function, respectively) do not
represent development of ‘renal failure’, as stated
in the review [1] and the original paper by Levin
et al. [2], but rather renal dysfunction, as evi-
denced by only a moderate increase in serum
creatinine levels. Specifically, it is stated in the
original paper [2] that the mean (± SD) increase in
serum creatinine concentration was 0.9 ±
0.6 mg ⁄dL in patients with normal baseline cre-
atinine levels, and 1.5 ± 1.4 mg ⁄dL in patients
with abnormal baseline creatinine levels. In addi-
tion, nephrotoxicity did not lead to discontinu-
ation of treatment for any of the patients in that
study, and was reversible in a considerable
proportion of patients. Other investigators, inclu-
ding our own group [3,4], have noted that the use
of intravenous colistin is associated with consid-
erably less nephrotoxicity than reported previ-
ously. In addition, Garnacho-Montero et al. [5]
reported an almost two-fold nephrotoxicity rate
among patients treated for A. baumannii ventila-
tor-associated pneumonia with imipenem when
compared to colistin-treated patients [5].
Another point of interest is that methods of
colistin administration other than the intravenous
route may have clinical value. These include
aerosolised (nebulised) administration of the anti-
biotic to patients with severe nosocomial pneu-
monia. The value of aerosolised colistin in the
prevention and treatment of infections caused by
Pseudomonas aeruginosa strains has already been
proven for patients with cystic fibrosis. In addi-
tion, intraventricular administration of colistin
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